Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.
Neff
Lisa M
LM
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, Boston, MA 02111, USA.
Weil
Michelle
M
Cole
Alan
A
Hedges
Thomas R
TR
Shucart
William
W
Lawrence
Donald
D
Zhu
Jay-Jiguang
JJ
Tischler
Arthur S
AS
Lechan
Ronald M
RM
D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000175:diagnosis / Q000188:drug therapy*; D000077204:Temozolomide
D018491:Dopamine Agonists; D003606:Dacarbazine; D011388:Prolactin; D000077204:Temozolomide